Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials
- 507 Downloads
A recent meta-analysis, which included non-placebo open-labeled trials, showed that fluoroquinolone prophylaxis reduces mortality in neutropenic patients, whereas two recent large trials failed to show a similar benefit. Therefore, we performed a meta-analysis of randomized, blinded, placebo-controlled trials of fluoroquinolone prophylaxis in neutropenic patients. We searched several databases for relevant trials in any language. We used random effects models for pooling dichotomous data and assessed the between-study inconsistency with I 2. Two investigators independently assessed the eligibility and quality of the included trials. A total of 2,721 patients were randomized in eight eligible trials. Compared to the placebo, there was a statistically non-significant but consistent decrease in mortality with fluoroquinolone prophylaxis (4.5% vs. 3.9%, relative risk (RR) 0.76, 95% confidence interval (CI) 0.54, 1.08, p = 0.13, I 2 = 0%). Significant inconsistency, however, accompanied the pooled analysis of febrile episode (39% vs. 31%, RR 0.76, 95% CI 0.55, 1.03, p = 0.08, I 2 = 96.5%). To an extent, this inconsistency was explained in the subgroup analyses by the type of patient population studied and the type of fluoroquinolone used (p for interaction ≤0.01 for both). The RR of febrile episodes for two trials of outpatients with solid tumors, including lymphomas, was RR 0.34 (95% CI 0.14, 0.80) and 0.60 (95% CI 0.33, 1.10) for two trials using levofloxacin prophylaxis. The RR in one of the two trials that used levofloxacin significantly favored the intervention, 0.76 (95% CI 0.70, 0.83). Fluoroquinolone prophylaxis reduces the risk of febrile episodes in neutropenic outpatients with solid tumors, including lymphomas, and is associated with a statistically non-significant, yet clinically important, decrease in mortality in all neutropenic patients. Prophylaxis with levofloxacin may reduce febrile episodes in neutropenic hematology patients and stem cell transplant recipients.
We would like to extend our special thanks to Dr. Michael Cullen, Cancer Centre, University Hospital Birmingham, Birmingham, UK, for providing us with the mortality data  and reviewing the paper.
Conflict of interest statement
None for all authors.
- 1.Bodey GP, Buckley M, Sathe YS, Freireich EJ (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340Google Scholar
- 2.Dale DC, Guerry DT, Wewerka JR, Bull JM, Chusid MJ (1979) Chronic neutropenia. Medicine (Baltimore) 58:128–144Google Scholar
- 5.Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRefGoogle Scholar
- 8.Fernández-Mosteirin N, Salvador-Osuna C, Gimeno Lozano JJ, Marco Lamata ML, Blasco Alberdi M, Rubio Felix D, Giralt Raichs M (2005) Incidence of febrile episodes in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation (in Spanish). An Med Interna 22:213–216PubMedGoogle Scholar
- 10.Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen J-M, Dybdahl B, Meyer P, Hopen G, Løkeland T, Grøttum K, Vie W, Langeland N (2005) A multi-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 37:455–464PubMedCrossRefGoogle Scholar
- 11.Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111–118PubMedCrossRefGoogle Scholar
- 22.Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7PubMedGoogle Scholar
- 24.Rafecas FJ et al (1989) Oral ciprofloxacin in the prophylaxis of bacterial infection in neutropenic patients. A randomized, double blind, comparative clinical study. Revista Espanola de Quimioterapia 2:174–177Google Scholar
- 27.Thomas X, Troncy J, Belhabri A, Thiebaut A, Bouheddou N, Michallet M, Fleurette J, Pivot C, Fiere D, Archimbaud E (2000) Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study (in French). Presse Med 29:1745–1751PubMedGoogle Scholar
- 32.Tascini C, Menichetti F, Bozza S, Fedele M, Preziosi R, Allegrucci M, Del Favero A, Micozzi A, Martino P, Bistoni F (1999) Molecular typing of fluoroquinolone-resistant and fluoroquinolone-susceptible Escherichia coli isolated from blood of neutropenic cancer patients in a single center. Clin Microbiol Infect 5:457–461PubMedGoogle Scholar
- 33.Martino R, Subira M, Altes A, López R, Sureda A, Domingo-Albós A, Pericas R, Brunet S (1998) Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 99:206–211PubMedCrossRefGoogle Scholar
- 35.Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368PubMedCrossRefGoogle Scholar